Gloucester's Istodax Gains FDA Approval Ahead Of New Regulatory Requirements
This article was originally published in The Pink Sheet Daily
With FDA's approval a week ahead of the PDUFA date, Gloucester Pharmaceuticals will bring its first product to market, the second HDAC inhibitor approved in cancer.
You may also be interested in...
Cancer drugs had a triumphant day at the European Medicines Agency on July 20, led by Pfizer’s Xalkori, with only one (Celgene’s Istodax) failing to make the grade.
Now called Ceptaris, the company is awaiting FDA approval of mechlorethamine gel, a topical formulation of a cytotoxin, for early-stage CTCL.
FDA orphan R&D grant and academic ties start to pay off for biotech's lead drug, a topical gel of a generic chemotherapy aimed at 20,000 patients with early-stage skin cancer.